Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Zynerba Pharma CS (ZYNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 128,450
  • Shares Outstanding, K 17,620
  • Annual Sales, $ 0 K
  • Annual Income, $ -32,010 K
  • 36-Month Beta 4.52
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.47

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.69
  • Number of Estimates 1
  • High Estimate -0.69
  • Low Estimate -0.69
  • Prior Year -0.63
  • Growth Rate Est. (year over year) -9.52%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.78 +0.15%
on 10/19/18
8.93 -23.96%
on 09/21/18
-1.07 (-13.61%)
since 09/19/18
3-Month
5.59 +21.47%
on 08/03/18
8.93 -23.96%
on 09/21/18
-3.63 (-34.84%)
since 07/19/18
52-Week
5.59 +21.47%
on 08/03/18
15.14 -55.14%
on 12/04/17
-2.87 (-29.71%)
since 10/19/17

Most Recent Stories

More News
Beverage Giants Backing a Cannabis Boom

The billion-dollar beverage giants have set their eyes on an entirely new industry, an industry that they fear will soon swallow them up if they don't get ahead of it. In a matter of days, Canada will...

TAP : 59.90 (+1.58%)
STZ : 222.93 (-0.96%)
NXTTF : 1.6900 (-8.43%)
ZYNE : 6.79 (-6.86%)
CGC : 46.85 (-4.21%)
Global Cannabis Market set to Grow as Multinational Companies Eye Entry

According to data compiled by Mordor Intelligence, the global cannabis market was valued at USD 7.7 Billion in 2016 and is expected to reach USD 65 Billion by 2023 while growing at a CAGR of 37% during...

ACAN : 2.9600 (-1.66%)
CANN : 3.1800 (-6.06%)
CNNRF : 6.4600 (+4.40%)
OGRMF : 5.1540 (-6.12%)
ZYNE : 6.79 (-6.86%)
The Hottest CBD Stocks

HENDERSON, NV / ACCESSWIRE / October 1, 2018 / With the DEA rescheduling CBD the top is off, and the time is now to find CBD companies before missing the boat.CBD is a very lucrative business, because...

CARA : 19.67 (-1.45%)
ACBFF : 9.9658 (-5.27%)
GWPH : 142.59 (-1.87%)
CIIX : 0.8051 (-9.54%)
ZYNE : 6.79 (-6.86%)
Zynerba Pharmaceuticals to Present at the Cantor Global Healthcare Conference

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that...

ZYNE : 6.79 (-6.86%)
Is the Options Market Predicting a Spike in Zynerba Pharmaceuticals (ZYNE) Stock?

Investors need to pay close attention to Zynerba Pharmaceuticals (ZYNE) stock based on the movements in the options market lately.

ZYNE : 6.79 (-6.86%)
CBD Stocks Set to Explode

HENDERSON, NV / ACCESSWIRE / September 19, 2018 / It's just a matter of time before medical marijuana will become legal in all 50 states. It's not surprising when you consider a recent poll shows 93%...

CARA : 19.67 (-1.45%)
GWPH : 142.59 (-1.87%)
CIIX : 0.8051 (-9.54%)
ZYNE : 6.79 (-6.86%)
Data Shows the Cannabis Industry Could Create Over 467,000 Jobs by 2022

According to recently provided data by Arcview Market Research, in partnership with BDS Analytics, the United States' legal cannabis market is projected to reach USD 11 Billion in consumer spending in...

IIPR : 40.28 (-3.73%)
CLSH : 0.9500 (+1.32%)
APHQF : 13.9390 (-6.38%)
TLRY : 145.30 (-4.74%)
ZYNE : 6.79 (-6.86%)
Cannabis Industry Growth Unperturbed by Federal Pushback

According to recent data published by Arcview Market Research in partnership with BDS Analytics, the United States' legal cannabis market is projected to reach USD 11 Billion in consumer spending in 2018,...

CLSH : 0.9500 (+1.32%)
APHQF : 13.9390 (-6.38%)
TLRY : 145.30 (-4.74%)
OGRMF : 5.1540 (-6.12%)
ZYNE : 6.79 (-6.86%)
Zynerba: 2Q Earnings Snapshot

DEVON, Pa. (AP) _ Zynerba Pharmaceuticals Inc. (ZYNE) on Thursday reported a loss of $12 million in its second quarter.

ZYNE : 6.79 (-6.86%)
The Rising Popularity of Legal Cannabis Products in a Variety of Businesses

According to recent data compiled by Research And Markets, the North American legal cannabis market value is projected to reach around USD 35 Billion by 2023, expanding at a CAGR of 27.1%. The North American...

CLSH : 0.9500 (+1.32%)
ACBFF : 9.9658 (-5.27%)
CBWTF : 0.9050 (-5.73%)
TRTC : 1.9300 (-3.50%)
ZYNE : 6.79 (-6.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade ZYNE with:

Business Summary

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company which focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. Its product candidates which are in clinical trial stage include ZYN002 and ZYN001 synthetic transdermal...

See More

Key Turning Points

2nd Resistance Point 7.58
1st Resistance Point 7.18
Last Price 6.79
1st Support Level 6.59
2nd Support Level 6.39

See More

52-Week High 15.14
Fibonacci 61.8% 11.49
Fibonacci 50% 10.36
Fibonacci 38.2% 9.24
Last Price 6.79
52-Week Low 5.59

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar